Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
2Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Extensive biopharmaceutical executive experience including President and CEO of Prometheus Biosciences and President of Salix Pharmaceuticals. Currently serves as CEO of Mirador Therapeutics and Chair of Apogee Therapeutics.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

NewAmsterdam Pharma Co N.V.

2024-01-01 · current

Confirmed by public sourceView source

Director

Apogee Therapeutics, Inc.

2023-01-01 · current

Confirmed by public sourceView source

Director

Perceptive Capital Solutions Corp

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Apogee Therapeutics, Inc.

Open Apogee Therapeutics, Inc. profile →

Director at Apogee Therapeutics, Inc.

2023-01-01 → End not stated

current · source reported

Observed: 2026-09-21

Apogee Therapeutic…Apogee Therapeutics, Inc.NewAmsterdam Pharm…NewAmsterdam Pharma Co N.V.Perceptive Capital…Perceptive Capital Solutions CorpMark C. McKenna

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec Def 14aPublic profile sourceSupports Director at Perceptive Capital Solutions Corp (NASDAQ: FRNM).Open sourceSource 2 · Sec FilingHLXC 10-K executive officersSupports Executive company, Executive title.Open sourceSource 3 · Sec FilingPCSC 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 4 · Sec FilingNAMS DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 5 · Sec FilingAPGE DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:mark-c-mckenna
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Apogee Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of NewAmsterdam Pharma Co N.V.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Perceptive Capital Solutions Corp1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board role · Source reportedBoard role: Vice Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Compensation, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Helix Acquisition Corp. III1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Mirador Therapeutics1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Perceptive Capital Solutions Corp1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · CorroboratedExecutive title: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Founder, Chairman and Chief Executive Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedMark C. McKenna is also linked to Mirador Therapeutics, Inc. as Founder, Chief Executive Officer and Chairman.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources10 records
  1. https://www.sec.gov/Archives/edgar/data/2017526/000114036126021304/ny20072405x2_def14a.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 6, 2026

    Supports: Director at Perceptive Capital Solutions Corp (NASDAQ: FRNM)

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  5. https://www.sec.gov/Archives/edgar/data/1936258/000119312525115995/d904380ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at NewAmsterdam Pharma Co N.V. (NASDAQ: NAMSW)

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  7. https://www.sec.gov/Archives/edgar/data/1974640/000095017025060147/apge-20250429.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Apogee Therapeutics, Inc. (NASDAQ: APGE)

  8. https://www.sec.gov/Archives/edgar/data/1936258/000119312525115995/d904380ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  9. https://www.sec.gov/Archives/edgar/data/1974640/000095017025060147/apge-20250429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/2017526/000114036126021304/ny20072405x2_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership